pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,490
stories
8d
FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
fda press
8d
An AI agent made a tiny drug R&D mistake. Then it kept going.
biopharma dive
8d
Ned Sharpless joins Hatteras, as Andrew Witty returns to the VC firm as chairman
endpoints
8d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
9d
No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins
biospace
9d
STAT+: PhRMA taps Eric Cantor as new CEO
stat
9d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
9d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
9d
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
biopharma dive
9d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
9d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
10d
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
10d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
10d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
10d
AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug
endpoints
10d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
10d
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
10d
Merck licenses a KRAS G12D inhibitor for $400M upfront
endpoints
10d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
10d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
10d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
10d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
10d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
10d
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
11d
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
fiercebiotech
11d
Opinion: AI is eroding the barriers that kept biological weapons rare
stat
11d
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
fiercebiotech
11d
6 immunology targets to sustain a mammoth I&I market
biospace
11d
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
11d
Recon: FDA approves drugs for Parkinson’s, bile duct cancer, rare soft tissue disease; Merck, Daiichi scrap application for ADC ...
raps
← prev
page 4 of 50
next →
